RGNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Regenxbio Inc. (RGNX) is not a good buy at this time for a beginner investor with a long-term focus. The stock is facing significant regulatory challenges, as evidenced by the FDA's rejection of its RGX-121 application, which has caused a sharp decline in its stock price. Additionally, the technical indicators suggest a bearish trend, and there are no strong trading signals or positive catalysts to justify an immediate investment.
The stock is in a bearish trend with the MACD histogram at -0.393, indicating negative momentum. The RSI_6 is at 11.544, signaling an oversold condition, but this does not necessarily indicate a reversal. The stock is trading below key support levels, with S1 at 8.581 and S2 at 7.768, and the pre-market price is 8.06, suggesting further downside risk.
The company's gross margin has improved significantly to 80.75%, up 65.44% YoY, indicating operational efficiency. Additionally, analysts still see potential in its RGX-202 program for DMD and ABBV-RGX-314 for wAMD, which could offer future opportunities.
The FDA's rejection of RGX-121 due to insufficient evidence of effectiveness and concerns about trial design has created significant regulatory uncertainty. The stock has also seen a sharp decline in price, and analysts have lowered their price targets. Furthermore, the biotech sector as a whole is facing challenges due to longer drug approval cycles and increased investment risks.
In Q3 2025, the company's revenue increased by 22.88% YoY to $29.73 million, and its gross margin improved to 80.75%. However, the company remains unprofitable, with a net loss of $61.94 million, albeit a slight improvement of 3.93% YoY. EPS also remains negative at -1.2, showing only marginal improvement of 2.56% YoY.
Analysts have lowered their price targets significantly following the FDA's rejection of RGX-121. Morgan Stanley reduced its target to $18 from $25, Goldman Sachs to $12 from $14, and Baird to $27 from $39. While some analysts maintain a Buy rating, the consensus reflects caution due to regulatory challenges and a lack of immediate catalysts.
